Suzhou, October 11, 2023 - Kintor
Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage
biotechnology company developing innovative small molecule and biological
therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained
conditional approval to conduct Phase II clinical trial in China by the
National Medical Products Administration (NMPA) for treatment of idiopathic
pulmonary fibrosis (IPF).IPF is a
chronic, progressive fibrosing interstitial pneumonia and one of the most fatal
interstitial pneumonias. The incidence of IPF is high, but due to the
relatively unnoticeable onset and progression, most patients are diagnosed in
the moderate and advanced stages, and the median survival time of patients from
the time of diagnosis is only 3~5 years[1]. There are currently no
effective therapies that can be used to stop the fibrosis process of IPF or
cure the disease, and no new drugs for treating IPF have been approved in the
past decade. There is a
………………………………
